Sign In
Buy IVVD
$1.10
-0.0400 (-3.51%)
At Close: Jun 03, 2026
Invivyd, Inc. (IVVD) Q3 2023 Earnings Call Transcript
09:41pm, Sunday, 12'th Nov 2023
Invivyd, Inc. (NASDAQ:IVVD ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Corporate Participants Scott Young - SVP, Investor Relations and Corporate Communications Dave Hering - Chief
Invivyd to Host Conference Call Discussing Third Quarter 2023 Financial Results and Business Highlights
04:01pm, Thursday, 02'nd Nov 2023
WALTHAM, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases
Invivyd to Participate in Upcoming Investor Conferences
04:01pm, Tuesday, 31'st Oct 2023
WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases
7 Biotech Stocks to Sell in September Before They Crash & Burn
08:17pm, Wednesday, 06'th Sep 2023
Investing in biotech stocks is not for the meek. Losses can be very large and occur very quickly.
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
02:17pm, Tuesday, 29'th Aug 2023
Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.
Invivyd, Inc. (IVVD) Q2 2023 Earnings Call Transcript
10:47pm, Saturday, 12'th Aug 2023
Invivyd, Inc. (NASDAQ:IVVD ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Gabriella Linville-Engler - Investor Relations Dave Hering - Chief Financial Officer Pete
Invivyd to Host Conference Call Discussing Second Quarter 2023 Financial Results and Business Highlights
04:01pm, Thursday, 03'rd Aug 2023
WALTHAM, Mass., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases
Invivyd to Participate at H.C. Wainwright's BioConnect Investor Conference
04:01pm, Tuesday, 25'th Apr 2023
WALTHAM, Mass., April 25, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases
Invivyd, Inc (IVVD) Q4 2022 Earnings Call Transcript
10:49am, Saturday, 25'th Mar 2023
Invivyd, Inc (NASDAQ:IVVD ) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Kyra Faircloth - Investor Relations Dave Hering - Chief Executive Officer Pete Schmidt - Chi
Invivyd to Host Conference Call Discussing Full Year 2022 Financial Results and Business Highlights
07:00am, Thursday, 16'th Mar 2023
WALTHAM, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases
IVVD Stock: 7.89% Decrease Explained
07:14am, Monday, 06'th Feb 2023
The stock price of Invivyd Inc (NASDAQ: IVVD) fell by 7.89% in the most recent trading session. This is why.
Why Shares of Invivyd Jumped This Week
05:59pm, Friday, 27'th Jan 2023
The company's shares have climbed along since an FDA announcement earlier this week.
Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why
01:32pm, Monday, 02'nd Jan 2023
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invivyd, Inc. (IVVD) CEO David Hering on Q3 2022 Results - Earnings Call Transcript
10:32am, Sunday, 13'th Nov 2022
Invivyd, Inc. (NASDAQ:IVVD ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Kyra Faircloth - VP, Government Affairs, Advocacy and Corporate Communication David Heri
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
04:01pm, Wednesday, 12'th Oct 2022
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity from
